Empirical Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Empirical Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-65,763	Closed	-$126K	–	468
2024 Q4	$126K	Buy	65,763 +63,874	+3,381%	+$29.6M	0.04%	327
2024 Q3	$879K	Buy	+1,889	New	+$907K	0.31%	92
2023 Q2	–	Sell	-2,377	Closed	-$749K	–	183
2023 Q1	$749K	Buy	+2,377	New	+$713K	0.72%	48
2022 Q2	–	Sell	-2,692	Closed	-$703K	–	181
2022 Q1	$703K	Buy	2,692 +827	+44%	+$196K	0.67%	48
2021 Q4	$410K	Buy	+1,865	New	+$363K	0.4%	92

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Empirical Asset Management's VRTX Position: Q1 2025 in Review

Empirical Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 65,763 shares — an estimated $126K sold.

Empirical Asset Management first reported a position in VRTX in Q4 2021 and held it in 5 quarters. The position peaked at $879K in Q3 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Empirical Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Empirical Asset Management sold 65,763 Vertex Pharmaceuticals shares in Q1 2025, an estimated $126K.
Empirical Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Empirical Asset Management's Vertex Pharmaceuticals position peaked at $879K in Q3 2024.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Empirical Asset Management's 13F filing for Q1 2025, filed 12 May 2025.